| scholarly article | Q13442814 |
| P2093 | author name string | Jing Wu | |
| Fei Ye | |||
| Peng Xie | |||
| Jian-Jun Chen | |||
| Peng Zheng | |||
| Hai-Yang Wang | |||
| Jin-Jun Xia | |||
| Wei-Wei Liang | |||
| Mei-Xue Dong | |||
| Bang-Min Yin | |||
| Feng-Li Deng | |||
| Jun-Xi Pan | |||
| P2860 | cites work | 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. | Q50663896 |
| Evaluation of a specific diagnostic marker for rheumatoid arthritis based on cyclic citrullinated peptide. | Q53182615 | ||
| High plasma norepinephrine levels in patients with major affective disorder | Q72955610 | ||
| Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment | Q79927257 | ||
| Network-Level Dysconnectivity in Drug-Naïve First-Episode Psychosis: Dissociating Transdiagnostic and Diagnosis-Specific Alterations | Q37644486 | ||
| Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC-MS-based metabonomics | Q37648213 | ||
| Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. | Q37733240 | ||
| Neurotransmitters, psychotropic drugs and microglia: clinical implications for psychiatry | Q38060240 | ||
| Differential diagnosis of bipolar disorder and major depressive disorder | Q38297850 | ||
| Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders | Q38396133 | ||
| Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. | Q38515241 | ||
| Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks | Q38657429 | ||
| Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. | Q38719357 | ||
| Targeted Metabolomic Pathway Analysis and Validation Revealed Glutamatergic Disorder in the Prefrontal Cortex among the Chronic Social Defeat Stress Mice Model of Depression | Q39418875 | ||
| Polygenic dissection of major depression clinical heterogeneity | Q40785234 | ||
| GABA and mood disorders: a brief review and hypothesis | Q40940358 | ||
| Effects of depressive symptoms and peripheral DAT methylation on neural reactivity to alcohol cues in alcoholism | Q41270254 | ||
| Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. | Q41270351 | ||
| Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment. | Q42465895 | ||
| A novel urinary metabolite signature for diagnosing major depressive disorder | Q43827823 | ||
| Psychopathological characteristics of bipolar and unipolar depression - potential indicators of bipolarity | Q44053988 | ||
| Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder. | Q44798660 | ||
| Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism | Q46565524 | ||
| Metabolomics identifies perturbations in amino acid metabolism in the prefrontal cortex of the learned helplessness rat model of depression | Q47365989 | ||
| The identification of metabolic disturbances in the prefrontal cortex of the chronic restraint stress rat model of depression | Q47444989 | ||
| Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis | Q47621925 | ||
| Altered plasma protein glycosylation in a mouse model of depression and in patients with major depression | Q47787059 | ||
| Metabolomic analysis reveals metabolic disturbances in the prefrontal cortex of the lipopolysaccharide-induced mouse model of depression | Q48057486 | ||
| Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells | Q48064073 | ||
| Identification and validation of argininosuccinate synthase as a candidate urinary biomarker for major depressive disorder | Q48074283 | ||
| In vivo study on the neurotransmitters and their metabolites change in depressive disorder rat plasma by ultra high performance liquid chromatography coupled to tandem mass spectrometry | Q48101685 | ||
| Ipsilateral hippocampal proteomics reveals mitochondrial antioxidative stress impairment in cortical-lesioned chronic mild stressed rats | Q48187900 | ||
| Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model | Q48236609 | ||
| Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey. | Q48592574 | ||
| Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. | Q48652486 | ||
| Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. | Q48658510 | ||
| Plasma metabonomics as a novel diagnostic approach for major depressive disorder. | Q48760949 | ||
| Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder | Q26823991 | ||
| Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue | Q26827833 | ||
| The Extrinsic Coagulation Pathway: a Biomarker for Suicidal Behavior in Major Depressive Disorder | Q27349460 | ||
| Biochemical markers subtyping major depressive disorder | Q28081652 | ||
| Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies | Q30245389 | ||
| Loss of cyclin-dependent kinase 5 from parvalbumin interneurons leads to hyperinhibition, decreased anxiety, and memory impairment | Q30405049 | ||
| Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates | Q30423149 | ||
| Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants | Q30887852 | ||
| A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. | Q30987882 | ||
| Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis | Q31127142 | ||
| Assessing the presence of shared genetic architecture between Alzheimer's disease and major depressive disorder using genome-wide association data. | Q33635647 | ||
| Biomarkers for depression: recent insights, current challenges and future prospects | Q33704099 | ||
| Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals | Q33990663 | ||
| Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders | Q34473840 | ||
| Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis | Q34530566 | ||
| Sex-specific urinary biomarkers for diagnosing bipolar disorder | Q34757521 | ||
| Diagnosis and definition of treatment-resistant depression | Q35111568 | ||
| Macaques exhibit a naturally-occurring depression similar to humans | Q35188855 | ||
| Metabolomics Approach Reveals Integrated Metabolic Network Associated with Serotonin Deficiency | Q35829940 | ||
| Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study | Q35848353 | ||
| Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder | Q35920768 | ||
| Plasma Metabolites Predict Severity of Depression and Suicidal Ideation in Psychiatric Patients-A Multicenter Pilot Analysis | Q36226766 | ||
| Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder | Q36351715 | ||
| Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives | Q36388848 | ||
| Identification and validation of urinary metabolite biomarkers for major depressive disorder | Q36508139 | ||
| Quantitative Proteomic Analysis Reveals Molecular Adaptations in the Hippocampal Synaptic Active Zone of Chronic Mild Stress-Unsusceptible Rats. | Q36634050 | ||
| Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid | Q36701832 | ||
| Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants | Q37307160 | ||
| Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins | Q37347834 | ||
| Abnormal GABAergic function and negative affect in schizophrenia. | Q37584271 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | major depressive disorder | Q42844 |
| metabolomics | Q12149006 | ||
| P304 | page(s) | 130 | |
| P577 | publication date | 2018-07-10 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study | |
| P478 | volume | 8 |
| Q92618317 | A Preliminary Study of Uric Metabolomic Alteration for Postpartum Depression Based on Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry |
| Q89628910 | Age-specific differential changes on gut microbiota composition in patients with major depressive disorder |
| Q92783333 | An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder |
| Q92832199 | Blood plasma metabolic profiling of pregnant women with antenatal depressive symptoms |
| Q90371599 | Circulating microRNA 134 sheds light on the diagnosis of major depressive disorder |
| Q90451202 | Feature of Heart Rate Variability and Metabolic Mechanism in Female College Students with Depression |
| Q99403576 | Identification of Potential Metabolite Markers for Middle-Aged Patients with Post-Stroke Depression Using Urine Metabolomics |
| Q100503970 | Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis |
| Q90399488 | Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment |
| Q100737112 | The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites |
| Q102369308 | The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies |
| Q90049649 | Unraveling the Serum Metabolomic Profile of Post-partum Depression |
Search more.